NASAL DRUG DELIVERY MODE MARKET ANALYSIS

Nasal Drug Delivery Mode Market, By Therapeutic Application (Asthma, Rhinitis, and Others), By Dosage Form (Powder, Gel. Spray, and Gel), By Container Type (Pressurized Container, Non Pressurized, and Container), By System Type (Multi- Dose, Bi-Dose, and Unit Dose), By End Users (Hospitals and Homecare Settings), By Distribution (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Market Drivers:

Increasing patient preference for nasal drug delivery (due to easy administration and better efficacy) is expected to boost the growth of the global nasal drug delivery mode market during the forecast period. For instance, in April 2022, Upperton Pharma Solutions launched the nasal delivery development platform, named UpperNose, to make it easier for innovators to access the capabilities necessary for the development of nasal dosage formulations.
Growing incidence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, is expected to augment the growth of the global nasal drug delivery mode market during the forecast period. For instance, according to the World Health Organization (WHO), COPD was the third leading cause of death worldwide, causing 3.23 million deaths, and asthma affected an estimated 262 million people and caused 455,000 deaths in 2019.

Market Opportunities:

Increase in demand for home healthcare devices and growing adoption of self-administration practices is expected to provide lucrative growth opportunities for players in the global nasal drug delivery mode market. For instance, in April 2022, Catalent announced the expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP) facility to provide world-class services for the development and manufacturing of unit and bi-dose nasal spray products.
Increasing prevalence of chronic diseases, such as chronic rhinosinusitis, is expected to offer significant growth opportunities for players in the global nasal drug delivery mode market. For instance, in June 2019, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.